Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML

Más betegség

• Other conditions deemed unsuitable for participation in this study by the investigator.

Laborértékek

• Subject has received treatment with a hypomethylating agent and/or other chemotherapeutic agents either conventional or experimental or targeted drug therapy for AML (except oral hydroxyurea and/or leukocytometry to reduce white blood cell count).

Egyéb

• Pregnant or lactating women.
• To the knowledge of the subject and investigator, subject may not be able to complete all study visits or procedures required by the study protocol, including follow-up visits, and/or be unable to comply with the required study procedures.

• Adults ≥ 18 years.
• Newly diagnosed CBFβ::MYH11(+) AML.
• Performance status 0-3 on the Eastern Cooperative Oncology Group (ECOG) Scale.
• Subject must voluntarily sign and date an informed consent, prior to the initiation of any screening or study-specific procedures.
  • Ferrara's criteria are used to determine whether a patient is unfit, and a patient is deemed unfit if at least one of the following criteria is met:
• Age>75 years.
• There are serious underlying heart, lung, kidney, liver complications.
• There are active infections that do not respond to anti-infective therapy.
• There is cognitive impairment.
• Other comorbidities that the doctor determines are not suitable for intensive chemotherapy.